Avtal | $24,000,000 | (Mar 20, 2026)
Parallel(FRANCE) | $20,000,000 | (Mar 20, 2026)
Claros | $30,000,000 | (Mar 20, 2026)
Certified by Founder
Lodge
Sionna Therapeutics
start up
United States
- Boston, MA
- 07/03/2024
- Series C
- $182,000,000
We are a life sciences company that is building on over a decade of extensive research on the genetic mutations associated with cystic fibrosis. We are developing first-in-class small molecules that are focused on a unique target with the potential to fully normalize CFTR function for the first time for the vast majority of people living with CF.
- Industry Biotechnology
- Website https://www.sionnatx.com/
- LinkedIn https://www.linkedin.com/company/sionna-therapeutics/
Latent | $80,000,000 | (Mar 20, 2026)
Corridor | $25,000,000 | (Mar 20, 2026)
RunSybil | $40,000,000 | (Mar 20, 2026)
PADO AI | $6,000,000 | (Mar 20, 2026)
Edra | $30,000,000 | (Mar 20, 2026)
Chalkie AI | $4,000,000 | (Mar 20, 2026)
Deeptune | $43,000,000 | (Mar 20, 2026)
SetSale | $2,000,000 | (Mar 19, 2026)
Laminar (YC S24) | $3,000,000 | (Mar 19, 2026)